Provided by Tiger Fintech (Singapore) Pte. Ltd.

Trevi Therapeutics, Inc.

6.91
+0.60009.51%
Post-market: 6.910.00000.00%19:27 EDT
Volume:1.58M
Turnover:10.59M
Market Cap:668.07M
PE:-14.71
High:7.02
Open:6.25
Low:6.14
Close:6.31
Loading ...

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

TIPRANKS
·
23 Apr

Trevi Therapeutics Price Target Maintained With a $24.00/Share by Needham

Dow Jones
·
08 Apr

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

PR Newswire
·
03 Apr

BRIEF-Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board

Reuters
·
26 Mar

Stock Track | Trevi Therapeutics Soars 6.40% on Strong Q4 Results and Positive Clinical Data in Chronic Cough Treatments

Stock Track
·
19 Mar

Stock Track | Trevi Therapeutics Soars 5.18% Pre-Market on Strong Q4 Results and Positive Clinical Data

Stock Track
·
19 Mar

B.Riley Financial Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)

TIPRANKS
·
19 Mar

B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating

MT Newswires Live
·
19 Mar

Q4 2024 Trevi Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
19 Mar

Trevi Therapeutics Inc : Needham Cuts Target Price to $24 From $25

THOMSON REUTERS
·
19 Mar

Stifel Nicolaus Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)

TIPRANKS
·
19 Mar

Trevi Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
19 Mar

Trevi Therapeutics 4Q Loss Widens, Cough Treatment Trials Move Forward

Dow Jones
·
19 Mar

Trevi Therapeutics: Completed Enrollment in Phase 2B Coral Trial in Ipf Patients With Chronic Cough in Feb 2025, With Topline Data Expected in Q2 2025

THOMSON REUTERS
·
19 Mar

Trevi Therapeutics: Ended 2024 With $107.6 Mln in Cash, Cash Equivalents & Marketable Securities, With Expected Cash Runway Into Second Half of 2026

THOMSON REUTERS
·
19 Mar

Trevi Therapeutics Q4 Pretax Profit USD -11.399 Million

THOMSON REUTERS
·
19 Mar

Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Dow Jones
·
19 Mar

Trevi Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
15 Mar

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

PR Newswire
·
12 Mar

TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study

Zacks
·
11 Mar